Please assess the completion status of the following clinical trial:

Trial Title: UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Clinical and phenotypic verification of B cell CLL and measurable disease. Immunophenotyping of the leukemic cells must demonstrate a monoclonal B cell population with immunophenotype consistent with CLL.~* Relapsed or refractory disease, defined by failure to achieve a partial response within 6 months of initiation of therapy, or a 50% increase of baseline disease measurements after achieving a clinical response.~* Not amenable to approved therapies.~* Prior Therapy: Must have progressed after purine-analog or alkylator based therapy, or be considered inappropriate for chemo-immunotherapy due to one of the following:~  * Del 17p, which is associated with poor response to chemo-immunotherapy, or~ * Age greater than 70, or~ * Age greater than 65 with one of the following:~ * Grade ≥ 3 neutropenia, anemia, or thrombocytopenia attributable to cumulative myelotoxicity from prior administration of cytotoxic agents (as documented by bone marrow biopsy obtained since last prior therapy), or~ * Clinically apparent autoimmune cytopenia which may be exacerbated by fludarabine therapy, or~ * Estimated creatinine clearance (eCCr) \<70 mL/min (as determined by the Cockcroft-Gault method), or~ * Eastern Cooperative Oncology Group (ECOG) performance status greater than 0.~* Has recovered from the toxic effects of prior therapy to their clinical baseline.~* Women of childbearing potential must agree not to become pregnant for the duration of the study. Both men and women must agree to use a barrier method of contraception for the duration of the study and until 10 weeks after the final dose of cirmtuzumab.~* Subjects must have at least one of the following indications for treatment:~  * Symptomatic or progressive splenomegaly;~ * Symptomatic lymph nodes, nodal clusters, or progressive lymphadenopathy;~ * Progressive anemia (hemoglobin ≤ 11 g/dL);~ * Progressive thrombocytopenia (platelets ≤ 100 x 10\^9/L);~ * Weight loss \> 10% body weight over the preceding 6 month period;~ * Fatigue attributable to CLL;~ * Fever or night sweats for \> 2 weeks without evidence of infection;~ * Progressive lymphocytosis with an increase of \> 50% over a 2-month period or an anticipated doubling time of less than 12 months.~* Subjects must have an ECOG performance status of 0-2.~* Adequate hematologic function~* Adequate renal function~* Adequate hepatic function~* Adequate coagulation tests~EXCLUSION CRITERIA:~* Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies.~* Patients who are currently receiving another investigational agent are excluded.~* Patients who have had chemotherapy (e.g., purine analogues, alkylating agents), immunotherapy, radiation therapy, or participation in any investigational drug treatment within 4 weeks of initiation of UC-961 or at any time during the study.~* Patients who have had prior (within 8 weeks of initiation of UC-961) or concurrent antibody therapy directed against CLL (i.e., Rituxan® and Campath®).~* Current infection requiring parenteral antibiotics.~* Active infection with HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV).~* Concurrent malignancy or prior malignancy within the previous 3 years (other than completely resected carcinoma in situ, prostate cancer, or localized non-melanoma skin cancer).~* Known central nervous system (CNS) involvement by malignancy.~* Untreated autoimmunity such as autoimmune hemolytic anemia, or immune thrombocytopenia.~* Uncompensated hypothyroidism (defined as thyroid-stimulating hormone (TSH) greater than 2x upper limit of normal not treated with replacement hormone).~* Presence of more than 55% pro-lymphocytes in peripheral blood. Patients with Richter's transformation are not excluded.~* Insufficient recovery from surgical-related trauma or wound healing.~* Impaired cardiac function including any of the following:~  * Myocardial infarction within 6 months of starting study drug;~ * A past medical history of clinically significant ECG abnormalities, including QTc 481 milliseconds or greater;~ * Other clinically significant heart disease (e.g., congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cirmtuzumab 0.015 - 0.03 mg/kg (Type: EXPERIMENTAL): Cohort 1: Cirmtuzumab 0.015 mg/kg for two 14-day cycles followed by cirmtuzumab 0.03 mg/kg for two 14-day cycles via intravenous (IV) infusion
- Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg (Type: EXPERIMENTAL): Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion
- Cirmtuzumab 0.5 - 1.0 mg/kg (Type: EXPERIMENTAL): Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion
- Cirmtuzumab 2.0 - 4.0 mg/kg (Type: EXPERIMENTAL): Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion
- Cirmtuzumab 8 mg/kg (Type: EXPERIMENTAL): Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion
- Cirmtuzumab 16 mg/kg (Type: EXPERIMENTAL): Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion
- Cirmtuzumab 20 mg/kg (Type: EXPERIMENTAL): Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete